10 results about "Cytostatic agents" patented technology

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

To provide an improved treatment strategy for multiple sclerosis (MS) patients, especially for long-term treatment. In particular, B-cell depleting MS therapies are provided without unnecessarily affecting serum levels of immunoglobulins.SOLUTION: A B-cell and / or T-cell inhibitor for use in the treatment of multiple sclerosis, wherein said treatment comprises: (a) optionally administering a B-cell and / or T-cell inhibitor other than ofatumumab; (b) monitoring serum IgG levels; (c) selecting ofatumumab as a B-cell and / or T-cell inhibitor if the serum IgG level decreases. A B-cell and / or T-cell inhibitor for use.SELECTED DRAWING: None

The present disclosure provides methods of using combination therapies to treat cancer. These methods are based on inhibiting cyclin proteins along with proteins along the Cyclin Axis. Thus, a method of the disclosure may generally be practiced by administering to an individual having cancer a cytocidal inhibitor of cyclin, along with a therapeutic agent that targets other molecules involved in pathways that promote cyclin activity. These therapeutic agents may target biomarkers on the surface of a cancer cell and that promote cyclin activity as well as intracellular proteins involved in pathways that affect, or are affected by, cyclin activity.

A product comprises: (a) a vector for specific expression of liver and / or spleen phagocytes, wherein the vector comprises a transgene operably linked to one or more expression control sequences; and (b) an immune checkpoint inhibitor or a Tr1 cell inhibitor.

The invention discloses a tumor cell inhibitor as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The core skeleton of the tumor cell inhibitor is Ph-CH2-C (= O)-NH-Ph '-CH = N-Ph '', the preparation method comprises the two steps of preparing an intermediate A through condensation purification of a 2-aminophenylacetic acid derivative and substituted benzaldehyde and preparing a target compound through reaction purification of the intermediate A and substituted acyl chloride, the steps are simple, the conditions are mild, and the yield is high. Experiments prove that the inhibitor has a remarkable proliferation inhibition effect on tumor cells of liver cancer, lung cancer, breast cancer and the like, dose-dependent inhibition is performed on the growth of transplanted tumors in vivo, the acute toxicity is low, the toxicity to normal cells is small, and the safety is superior to that of cis-platinum. The compound disclosed by the invention can be used for preparing tumor treatment medicines, can be prepared into oral preparations and injection preparations, and has a wide clinical application prospect.

The application discloses a kind of by adjusting cannabinoid system and its downstream passage to prevent and / or treat chronic pruritus, it is related to the field of biological medicine technology.It is specifically related to at least one of CB2R agonist, microglial cell inhibitor, p-p38 inhibitor, IL-1 beta signal blocking agent in the application of preparation of the drug for preventing and / or treating chronic pruritus.The application first proves that CB2R expressed in spinal cord microglial cell plays an indispensable role in the formation and maintenance process of chronic pruritus, and by targeting CB2R expressed in spinal cord microglial cell, the function of microglial cell becomes a new treatment way of chronic pruritus.CB2R agonist, microglial cell inhibitor, p-p38 inhibitor, IL-1 beta signal blocking agent can effectively reduce spontaneous scratching times.

Multispecific binding molecules (MBMs) comprising an N-terminal scFv, a first Fab and a second Fab, MBM conjugates comprising the MBMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the MBMs and MBM conjugates, methods of using the MBMs, MBM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.

The invention belongs to the technical field of medical instruments, and discloses a low-temperature storage device for cancer cell inhibitors, a low-temperature storage box is connected with a first spring, the first spring is connected with a supporting plate, the supporting plate is rotatably connected with a rotating cylinder, the rotating cylinder is provided with a plurality of clamping blocks, the top of each clamping block is provided with an inclined part, and the clamping blocks are connected with a fixing assembly; the low-temperature storage box is connected with a limiting cylinder, and a plurality of first clamping grooves and second clamping grooves which are alternately arranged are formed in the bottom of the limiting cylinder. A push cylinder is slidably connected into the limiting cylinder, and sawteeth matched with the inclined part of the clamping block are arranged on the edge of the bottom of the push cylinder. The top of the push cylinder is connected with a button; the top of the low-temperature storage box is provided with a concave part, the concave part is provided with an opening, and the opening is detachably connected with an end cover assembly. The technical problems that when some existing low-temperature storage devices take and place medicines, the temperature in the box is likely to rise suddenly, the set temperature can be recovered after a door is opened and closed for a long time, medicine activity decline is aggravated, and the medicines are likely to be polluted due to manual medicine taking are solved.

Provided and exemplified herein are inhibitors of B-reg cells (regulatory B cells) for use in a combination therapy with an ICI. Useful B-reg inhibitors include antibodies that bind CD19 and CD38, for example, a bispecific antibody that binds CD19 and CD38. Such bispecific antibodies that bind CD19 and CD38 can be characterized by an antibody comprising a CD19-binding domain and a CD38-binding domain.

An organism comprising (a) a vector for phagocytic cell-specific expression of the liver and / or spleen, wherein the vector comprises a transgene operably linked to one or more expression regulatory sequences, and (b) an immune checkpoint inhibitor or a Tr1 cell inhibitor.